LGND
LGND
US53220K5048
Ligand Pharmaceuticals Incorpor
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue 268.087.000 167.133.000
60.4%
Cost of Revenue 14.549.000 11.074.000
31.4%
Gross Profit 253.538.000 156.059.000
62.5%
206.339.000 133.038.000
55.1%
Operating Income 47.199.000 23.021.000
105.0%
Pretax Income 158.960.000 2.518.000
6212.9%
Net Income Common Stockholders 124.453.000 -4.032.000
3186.6%
-- --
--
-- --
--
ende